Werewolf Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
14
- Stock Symbol
-
HOWL
- Investments
-
1
- Share Price
-
$0.94
- (As of Friday Closing)
Werewolf Therapeutics General Information
Description
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
Contact Information
Website
www.werewolftx.comCorporate Office
- 300 Wyman Street
- Suite 300
- Waltham, MA 02451
- United States
Corporate Office
- 300 Wyman Street
- Suite 300
- Waltham, MA 02451
- United States
Werewolf Therapeutics Stock Performance
As of 20-Nov-2026, Werewolf Therapeutics’s stock price is $0.94. Its current market cap is $46M with 48.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.94 | $0.99 | $0.27 - $1.20 | $46M | 48.6M | 5.63M | -$0.58 |
Werewolf Therapeutics Financials Summary
As of 30-Sep-2026, Werewolf Therapeutics has a trailing 12-month revenue of $21M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 22,838 | 2,339 | (20,096) | 61,832 |
| Revenue | 21,000 | 0 | 1,885 | 19,943 |
| EBITDA | (21,852) | (57,022) | (70,718) | (39,881) |
| Net Income | (28,120) | (60,822) | (70,515) | (37,368) |
| Total Assets | 42,753 | 69,396 | 126,929 | 174,833 |
| Total Debt | 0 | 37,671 | 37,087 | 51,923 |
Werewolf Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Werewolf Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Werewolf Therapeutics Comparisons
Industry
Financing
Details
Werewolf Therapeutics Competitors (6)
One of Werewolf Therapeutics’s 6 competitors is PMV Pharma, a Formerly VC-backed company based in Princeton, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PMV Pharma | Formerly VC-backed | Princeton, NJ | ||||
| Xilio Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Nektar Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Centrose | Venture Capital-Backed | Madison, WI |
Werewolf Therapeutics Patents
Werewolf Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026072455-A1 | Single domain human serum albumin antibodies | Pending | 26-Sep-2024 | ||
| WO-2026006413-A1 | Il-12 prodrugs, methods of use and pharmaceutical compositions | Pending | 25-Jun-2024 | ||
| WO-2025250977-A1 | Cancer therapy using il-2 prodrug | Pending | 31-May-2024 | ||
| WO-2025240781-A2 | Modified antibodies and immunoglobulin formats | Pending | 15-May-2024 | ||
| WO-2025240781-A3 | Modified antibodies and immunoglobulin formats | Pending | 15-May-2024 | C07K16/2809 |
Werewolf Therapeutics Signals
Werewolf Therapeutics Acquisitions (1)
Werewolf Therapeutics’s most recent deal was a Reverse Merger with Ambros Therapeutics. The deal was made on 21-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ambros Therapeutics | 21-Aug-2026 | Reverse Merger | Biotechnology |
Werewolf Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.35 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Werewolf Therapeutics FAQs
-
When was Werewolf Therapeutics founded?
Werewolf Therapeutics was founded in 2017.
-
Where is Werewolf Therapeutics headquartered?
Werewolf Therapeutics is headquartered in Waltham, MA.
-
What is the size of Werewolf Therapeutics?
Werewolf Therapeutics has 14 total employees.
-
What industry is Werewolf Therapeutics in?
Werewolf Therapeutics’s primary industry is Drug Discovery.
-
Is Werewolf Therapeutics a private or public company?
Werewolf Therapeutics is a Public company.
-
What is Werewolf Therapeutics’s stock symbol?
The ticker symbol for Werewolf Therapeutics is HOWL.
-
What is the current stock price of Werewolf Therapeutics?
As of 20-Nov-2026 the stock price of Werewolf Therapeutics is $0.94.
-
What is the current market cap of Werewolf Therapeutics?
The current market capitalization of Werewolf Therapeutics is $46M.
-
What is Werewolf Therapeutics’s current revenue?
The trailing twelve month revenue for Werewolf Therapeutics is $21M.
-
Who are Werewolf Therapeutics’s competitors?
PMV Pharma, Xilio Therapeutics, Immunocore Holdings, Nektar Therapeutics, and Centrose are some of the 6 competitors of Werewolf Therapeutics.
-
What is Werewolf Therapeutics’s annual earnings per share (EPS)?
Werewolf Therapeutics’s EPS for 12 months was -$0.58.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process